Novo Nordisk got the regulatory green light to begin promoting that its popular anti-obesity drug Wegovy also boosts heart health–a claim that could increase pressure on reluctant employers and insurers to pay for the drug.
Novo Nordisk got the regulatory green light to begin promoting that its popular anti-obesity drug Wegovy also boosts heart health–a claim that could increase pressure on reluctant employers and insurers to pay for the drug.